Life-sciences deal intelligence
Get to the
deal first.
DealNode is the deal-intelligence map for life sciences: every company, investor, trial, and licensing deal in one searchable, cited atlas, organized by the science. Spot the opportunity, run diligence in an afternoon, and move before the market catches up.
- Source
- Find companies, assets, and investors by indication, mechanism, and phase, not by an industry tag and a keyword.
- Diligence
- Walk in with the landscape already built. Competitors, trials, and deal history on one page, every fact cited.
- Edge
- Know the financing, readout, or license the day it lands, and see who moved before it.
The whole market, on one map
An atlas of biotech money & molecules.
Screen any indication by stage and science, and the map resolves from cited events, with no manual research. This is one plate of many.
Cardiometabolic: private companies by stage
Plate 04 · auto-generated · rebuilt dailySmall molecule
4 financed this year · 2 stealth syndicates detected
Gene therapy
1 clinical hold in adjacent target class
Peptide / GLP-adjacent
Syndicate overlap with 3 top-decile funds
RNA
2 licensing options signed since January
Small molecule
3 readouts due within two quarters
Heart failure
$430M raised across last 4 rounds
Lipid disorders
1 crossover round closed pre-readout
Devices + drug
M&A interest reported in trade press
Illustrative plate. Every cell is a live query. Companies, stage, capital, and syndicates resolve from cited events.See the full sample map →
Who it's for
Find what
you came for.
Three sides of the same market, one map. Each gets back the weeks of manual landscape work.
Source and diligence with the landscape already built
- Screen companies by the science. Filter by indication, mechanism, and phase, not by an industry tag and a keyword.
- See who funded similar science. Syndicates, co-investor patterns, and who entered before the readouts.
- Walk into diligence with the map done. Competitors, trials, and deal history on one page, every fact cited.
Know a space in an afternoon, not a quarter.
Find targets, partners, and the story on any company
- Shortlist M&A and in-licensing candidates. Rank by pipeline fit: phase, modality, and partnership status.
- Spot the unpartnered assets. Find them in your indication before the banker's book reaches you.
- Pull a cited dossier in seconds. On any company you meet, at a conference, in a deck, in the news.
One query: “Phase 2, your indication, no large-pharma partner.”
Raise from investors who actually back your science
- Target investors by what they fund. Modality, stage, and indication, based on deals, not directories.
- See who co-invests with whom. One warm lead becomes a mapped syndicate.
- Track your competitive field. Financings, readouts, and partnerships around your program, as they happen.
A target list built on evidence, not scraped lists.
The system
What that
looks like.
Six things the atlas does that your current stack of databases, alerts, and spreadsheets doesn't.
Filter by what determines value
Indication, mechanism of action, modality, clinical phase, trial status, partnership and licensing terms. The dimensions a life-sciences deal actually turns on, all first-class.
Any company, one cited page
Financing history, syndicate, pipeline, trials, and partners, assembled automatically from cited events and current as of this morning. Ready before your next meeting.
See the relationships behind the deal
Syndicate maps, co-investor patterns, licensing chains, and the people who move between companies. The context that explains why a deal happened, and predicts the next one.
Plain questions, computed answers
“Which funds led ADC rounds within 90 days of a positive Phase 2?” Answered from the map in seconds, with every source shown, not free-associated by a chatbot.
Alerts on what you track
Follow companies, investors, targets, or whole indications. A financing, readout, or license in your field reaches you the day it happens, with sources attached.
Every fact traceable to a document
Each relationship stores its source and verbatim snippet. Put the answer in front of an investment committee or a board without caveats.
Versus generalist databases
They see an industry. We see the science.
Generalist deal databases file a biotech under "Industry: Biotechnology" and move on. In life sciences, the value lives in what they don't model: the indication, the mechanism, the trial, the partnership. That's the data model here, not an add-on.
| Dimension | Generalist databases | DealNode |
|---|---|---|
| Classification | Industry tags and keywords | ■Indication, mechanism of action, modality |
| Clinical context | Not modeled | ■Trials, phases, and readouts linked to every company |
| Deal detail | Rounds and amounts | ■Plus licensing structure, options, milestones, partnership status |
| A real question | Keyword search, then a week of spreadsheets | ■One query: “Phase 2 ADCs without a large-pharma partner” |
| Trust | “Source: proprietary” | ■Citation and snippet on every relationship |
Early access
Put your market
on the map.
We're onboarding a first cohort of life-sciences investors, BD and corporate-development teams, and founders. Tell us the indications you cover, and we'll open your view of DealNode.